Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed

被引:26
作者
Belgi, AS [1 ]
Azeez, M
Hoyle, C
Williams, REA
机构
[1] Glan Clwyd Gen Hosp, Dept Dermatol, Bodelwyddan LL18 5UJ, Wales
[2] Glan Clwyd Gen Hosp, Dept Haematol, Bodelwyddan LL18 5UJ, Wales
关键词
D O I
10.1111/j.1365-2230.2005.01941.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
引用
收藏
页码:143 / 143
页数:1
相关论文
共 2 条
[1]   Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab) [J].
Cooper, HL ;
Healy, E ;
Theaker, JM ;
Friedmann, PS .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2003, 28 (04) :366-368
[2]   Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations [J].
España, A ;
Fernández-Galar, M ;
Lloret, P ;
Sánchez-Ibarrola, AF ;
Panizo, C .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (06) :974-976